• Immatics published an ESMO presentation reporting Phase 1 results for its investigational PRAME-directed T-cell therapy IMA203CD8 in solid tumors.
• Objective response rate reached 51% among 90 evaluable patients; confirmed objective response rate was 41%.
• Higher-dose treatment in 20 patients with gynecologic cancers yielded a 60% objective response rate; confirmed responses reached 55%.
• Responses remained ongoing beyond 2.5 years across indications.
• Dose-limiting toxicities occurred in four of 98 patients; the maximum tolerated dose was not reached at 12.5 billion cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.